Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory AIDS-Related Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Intermediate- or high-grade non-Hodgkin's lymphoma or Hodgkin's disease~  * Failed to achieve complete remission with initial therapy OR~ * Relapsed after initial therapy~* May be in complete remission after salvage therapy~* Sensitive to most recent chemotherapy~  * Improvement of at least 25% in bidimensional tumor measurements OR~ * Improvement in evaluable disease sustained over 4 weeks~* Measurable or evaluable disease~* HIV-1 positive~* CD4 greater than 50 cells/mm\^3 (unless not receiving optimal antiretroviral therapy)~* HIV RNA less than 110,000 copies/mL (unless not receiving optimal antiretroviral therapy)~* No active leptomeningeal or parenchymal CNS involvement NOTE: A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of indolent or aggressive lymphoma will replace the former terminology of low, intermediate, or high grade lymphoma. However, this protocol uses the former terminology.~PATIENT CHARACTERISTICS:~Age:~* Physiologic 18 and over~Performance status:~* Karnofsky 70-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~Hepatic:~* AST no greater than 3 times upper limit of normal~* Bilirubin no greater than 2.0 mg/dL (unless receiving indinavir)~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No history of cardiac disease~* LVEF at least 45%~Pulmonary:~* No history of symptomatic pulmonary disease~* DLCO at least 60%~Other:~* No active opportunistic infections~* No cytomegalovirus retinitis or pneumonitis requiring maintenance therapy~* No sensitivity to E. coli-derived products~* Not pregnant~* Negative pregnancy test~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* At least 1 week since prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* Chronic suppressive therapy for infection allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).